Breaking Finance News

A statement released earlier today by Leerink Swann about EXACT Sciences (NDAQ:EXAS) bumps the target price to $50.00

Yesterday EXACT Sciences (NDAQ:EXAS) traded 3.69% higher at $45.28. The company’s 50-day moving average is $40.21 and its 200-day moving average is $32.94. The last closing price is up 36.60% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 942,130 shares of the stock were exchanged, down from an average trading volume of 1,724,700

Leerink Swann bumped up the target of EXACT Sciences (NDAQ:EXAS) to $50.00 indicating a possible upside of 0.10%.

Previously on 7/26/2017, Lake Street reported on EXACT Sciences (NDAQ:EXAS) raised the target price from $30.00 to $41.00. At the time, this indicated a possible upside of 0.03%.

See Chart Below

EXACT Sciences (NDAQ:EXAS)

EXACT Sciences has a 52 week low of $13.05 and a 52 week high of $45.18 The company’s market cap is currently $0.

In addition to Leerink Swann reporting its target price, a total of 10 brokers have issued a report on the stock. The consensus target price is $8.55 with 5 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 7 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About EXACT Sciences (NDAQ:EXAS)

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.